Your browser is no longer supported. Please, upgrade your browser.
Chinook Therapeutics, Inc.
Index- P/E- EPS (ttm)-6.20 Insider Own0.20% Shs Outstand42.38M Perf Week7.29%
Market Cap653.81M Forward P/E- EPS next Y-2.54 Insider Trans14.64% Shs Float18.08M Perf Month-10.82%
Income-81.60M PEG- EPS next Q-0.61 Inst Own75.00% Short Float5.01% Perf Quarter0.82%
Sales0.80M P/S817.26 EPS this Y75.70% Inst Trans349.30% Short Ratio7.31 Perf Half Y-7.99%
Book/sh25.41 P/B0.63 EPS next Y2.70% ROA-26.60% Target Price- Perf Year-1.24%
Cash/sh6.02 P/C2.64 EPS next 5Y9.00% ROE-68.70% 52W Range10.50 - 21.68 Perf YTD0.25%
Dividend- P/FCF- EPS past 5Y-7.20% ROI-16.20% 52W High-26.66% Beta0.06
Dividend %- Quick Ratio11.10 Sales past 5Y-59.20% Gross Margin- 52W Low51.43% ATR1.12
Employees96 Current Ratio11.10 Sales Q/Q- Oper. Margin- RSI (14)50.97 Volatility6.68% 7.68%
OptionableYes Debt/Eq0.00 EPS Q/Q75.70% Profit Margin- Rel Volume0.91 Prev Close15.24
ShortableYes LT Debt/Eq0.00 EarningsApr 07 AMC Payout- Avg Volume123.71K Price15.90
Recom1.50 SMA20-0.52% SMA50-2.60% SMA2006.87% Volume112,394 Change4.33%
Jan-06-21Initiated Wedbush Outperform $28
Dec-10-20Initiated Cantor Fitzgerald Overweight $31
Nov-16-20Initiated H.C. Wainwright Buy $28
Nov-02-20Initiated Evercore ISI Outperform $32
Oct-20-20Upgrade Oppenheimer Perform → Outperform $25
Apr-15-21 08:15AM  
Apr-08-21 04:30PM  
Apr-07-21 04:05PM  
Apr-05-21 08:15AM  
Apr-01-21 04:15PM  
Mar-30-21 04:26PM  
Mar-16-21 08:15AM  
Mar-02-21 04:15PM  
Mar-01-21 08:15AM  
Feb-23-21 08:15AM  
Feb-17-21 04:15PM  
Feb-02-21 08:15AM  
Jan-07-21 03:01AM  
Jan-04-21 08:15AM  
Dec-08-20 08:15AM  
Nov-30-20 04:15PM  
Nov-18-20 04:15PM  
Nov-10-20 08:15AM  
Nov-05-20 05:07PM  
Oct-22-20 11:15AM  
Oct-09-20 12:45PM  
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase Ib trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. The company is headquartered in Seattle, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DOBMEIER ERICPresident, CEODec 21Option Exercise0.3520,0007,00076,837Dec 22 07:47 PM
DOBMEIER ERICPresident, CEODec 09Buy13.072,00026,15056,837Dec 10 05:38 PM
DOBMEIER ERICPresident, CEODec 08Buy13.242,00026,48354,837Dec 10 05:38 PM
DOBMEIER ERICPresident, CEONov 23Buy13.6792912,69952,837Nov 23 07:26 PM
DOBMEIER ERICPresident, CEONov 20Buy13.695717,81751,908Nov 23 07:26 PM
DOBMEIER ERICPresident, CEONov 19Buy13.505006,75051,337Nov 23 07:26 PM
DOBMEIER ERICPresident, CEONov 11Buy13.752,50034,37550,837Nov 13 06:13 PM
DOBMEIER ERICPresident, CEONov 10Buy13.862,00027,72048,337Nov 13 06:13 PM